BioNTech SE (ETR:22UA)
Germany
· Delayed Price · Currency is EUR | Market Cap | 20.90B |
| Revenue (ttm) | 2.75B |
| Net Income (ttm) | -766.00M |
| Shares Out | n/a |
| EPS (ttm) | -3.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 365 |
| Average Volume | 2,123 |
| Open | 85.85 |
| Previous Close | 86.70 |
| Day's Range | 85.85 - 87.50 |
| 52-Week Range | 69.70 - 124.60 |
| Beta | 1.36 |
| RSI | 49.05 |
| Earnings Date | May 5, 2025 |
About BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in ph... [Read more]
Financial Performance
Financial StatementsNews
BioNTech to invest $1.3B in the U.K. to boost R&D efforts
The FDA Is Limiting Covid Shots. But Moderna, Vaccine Stocks Jumped.
The FDA said Tuesday it will limit future Covid vaccines to older and at-risk Americans. The move buoyed Moderna, BioNTech and Novavax.
BioNTech plans up to $1.33 billion investment in the United Kingdom
German vaccine maker BioNTech said on Tuesday that it plans to invest up to 1 billion pounds ($1.33 billion) over the next ten years to broaden its research and development activities in the United Ki...
Novavax Wins Limited FDA Nod For COVID Shot—Cleared Only For Seniors, High-Risk Groups Amid Safety Scrutiny
The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.’s (NASDAQ: NVAX) COVID-19 vaccine, restricting its use to people 65 and older and those 12 and up with underlying he...
CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE
European Patent Office largely dismisses opposition filed by BioNTech SE, Pfizer Inc., and others in December 2023 challenging validity of EP 4 023 755 B1 and maintains the patent subject to amendment...
BioNTech says bispecific antibody BNT324 is competitive against Summit's ivonescimab
BioNTech's BNT324 aims to outpace rivals in cancer treatment with its unique bispecific antibody design. Read more here.
New vaccine chief rocks pharmaceutical stocks
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump.
Why BioNTech Stock Got Trounced on Tuesday
SA analyst downgrades: COP, ON, BNTX, SKX, ALIZY, SFM
Seeking Alpha analysts have issued stock rating upgrades for ConocoPhillips, ON Semiconductor, BioNTech, Skechers, Allianz and Sprouts. Read more here.
BioNTech: mRNA Challenges Amid Regulatory Uncertainty (Rating Downgrade)
BioNTech maintains €15.85B reserves as COVID revenues fall and R&D grows.
BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion
BioNTech SE (NASDAQ: BNTX) on Monday reported a first-quarter per-share loss of $1.82 (1.73 euros), up from 1.31 euros reported a year ago compared to beating the consensus of $2.02 . The COVID-19 va...
BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion
BioNTech SE BNTX on Monday reported a first-quarter per-share loss of $1.82 (1.73 euros), up from 1.31 euros reported a year ago compared to beating the consensus of $2.02.
BioNTech SE (BNTX) Q1 2025 Earnings Call Transcript
BioNTech SE 2025 Q1 - Results - Earnings Call Presentation
BioNTech GAAP EPS of -€1.73, revenue of €182.8M; reaffirms FY25 outlook
BioNTech press release (BNTX): Q1 GAAP EPS of -€1.73. Revenue of €182.8M (-2.6% Y/Y). Cash and cash equivalents plus security investments as of March 31, 2025, reached €15,854.4 million,
BioNTech Announces First Quarter 2025 Financial Results and Corporate Update
Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A 1 , and mRNA...
BioNTech says Novartis executive Zapata-Gomez to become CFO
German COVID-19 vaccine maker BioNTech said on Monday that Ramon Zapata-Gomez will become its new finance chief from July 1.
BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer
Mainz, Germany, May 5, 2025 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Ramón Zapata-Gomez to the Management Boa...
Earnings Scheduled For May 5, 2025
Companies Reporting Before The Bell • Recursion Pharmaceuticals (NASDAQ: RXRX) is likely to report quarterly loss at $0.52 per share on revenue of $18.08 million. • Freshpet (NASDAQ: FRPT) is estima...
BioNTech Q1 2025 Earnings Preview
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today
Prediction: 1 Biotech Stock That Could Surpass Pfizer by 2030
Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a $128 billion market cap. Renowned for its blockbuster drugs like Lipitor an...
BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025
MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer immunother...
BioNTech Surges On Summit's Coattails. But Can They Take On Merck?
BioNTech stock rocketed Wednesday after rival Summit Therapeutics unveiled promising results for a novel approach to lung cancer treatment.
BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025
MAINZ, Germany, April 22, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2025 on Monday, May 5, 2025. Additi...